Addendum. 8. Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes—2020. Diabetes Care 2020;43(Suppl. 1):S89

Addendum. 8. Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes—2020. Diabetes Care 2020;43(Suppl. 1):S89–S97

Published:2020-06-05 Issue:8 Volume:43 Page:1980-1980
ISSN:0149-5992
Container-title:Diabetes Care
language:en
Short-container-title:Dia Care

Author:

Publisher

American Diabetes Association

Subject

Advanced and Specialised Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference1 articles.

1. U.S. Food and Drug Administration . FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market. Potential risk of cancer outweighs the benefits. 13 February 2020 [FDA Drug Safety Communication]. Available from https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-withdrawal-weight-loss-drug-belviq-belviq-xr-lorcaserin-market

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial;Endocrine;2024-06-08

2. Remission in Type 2 DM with Personalized Medical Interventions Including Life Style Modification and Appropriate Pharmacotherapy - A Case Report;Journal of Endocrinology and Metabolism Research;2022-08-28

3. Comparison of efficacy between dipeptidyl peptidase-4 inhibitor and sodium–glucose cotransporter 2 inhibitor on metabolic risk factors in Japanese patients with type 2 diabetes mellitus: Results from the CANTABILE study;Diabetes Research and Clinical Practice;2021-10

4. The Risks of Polycystic Ovary Syndrome and Diabetes Vary by Ethnic Subgroup Among Young Asian Women;Diabetes Care;2021-04-26

5. Education of an Overweight or Obese Diabetic Patient in Primary Health Care Centers;Рецепт;2021-02-15